Tag Archives: paclitaxel

FDA Approves Halaven for Late-Stage Breast Cancer

Posted on November 22, 2010 by wngai

Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →

Posted in Breast cancer, Cancer | Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda | Comments Off

Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Posted on July 25, 2010 by wngai

Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations. The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading →

Posted in Lung Cancer, Non Small Cell Lung Cancer | Tagged carboplatin, EGFR, epidermal growth-factor receptor, gefitinib, Iressa, Lung Cancer, mutations, Non small cell lung cancer, paclitaxel, Survival | Comments Off

Avastin Boosts Progression-Free Survival in Ovarian Cancer Patients

Posted on June 26, 2010 by wngai

Adding bevacizumab (Avastin) to chemotherapy, followed by bevacizumab as maintenance therapy, can significantly prolong progression-free survival in women with advanced ovarian cancer. The study consisted of 1873 women with newly diagnosed stage III (macroscopic residual disease) or stage IV ovarian, primary peritoneal, … Continue reading →

Posted in Cancer, Ovarian Cancer | Tagged Avastin, bevacizumab, carboplatin, maintenance therapy, Ovarian Cancer, paclitaxel, Survival | Comments Off

Alternative Treatment Options for Late Stage Lung Cancer Patients

Posted on March 7, 2010 by wngai

Paclitaxel plus carboplatin(PC) is the current standard regimen for advanced or metastatic non-small-cell lung cancer (NSCLC) patients. However, paclitaxel is associated with serious toxicity such as peripheral neuropathy. A tria,l published in October version of the Annals of Oncology, was … Continue reading →

Posted in Cancer, Lung Cancer | Tagged carboplatin, chemotherapy, gemcitabine, Lung Cancer, NSCLC, paclitaxel, Stage III, Stage IV, Survival | Comments Off